UAE-made diagnostic kits are about to travel further

Making a good diagnostic kit is only half the job. Getting it into hospital and laboratory hands is the other half, and that is where many regional innovators stall. A new agreement in Abu Dhabi aims to fix exactly that problem for one UAE manufacturer.

Mubadala Bio, through its company Al Ittihad Drug Store (IDS), has signed a regional distribution agreement with Baynouna Gene Solutions (BGS50). IDS will expand access to advanced molecular diagnostic kits designed and manufactured in the UAE. The deal was signed at the 46th ICMM World Congress of Military Medicine in Abu Dhabi.

Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, signed for the group. Dr. Omar Najim, CEO of Baynouna Gene Solutions, signed for the manufacturer. Dr. Bakheet Al Katheeri, Chairman of Mubadala Bio, Dr. Essam Mohamed, Group CEO of Mubadala Bio, and Prof. Habiba Alsafar, Deputy Chair of Baynouna, witnessed the signing.

How will it work?

The split of roles is simple. Baynouna designs and produces the molecular diagnostics. IDS sells and delivers them through its established UAE and regional distribution network.

IDS sits within Mubadala Bio's Pharma Logistics vertical, which supports distribution and market access for medicines, medical devices and healthcare products across the UAE. Baynouna's kits now enter that existing channel rather than having to build one from scratch.

Baynouna brings genuine technical credentials. Dr. Najim says the company was the first in the Middle East to manufacture commercial primers using enzymatic DNA synthesis. Prof. Alsafar describes it as pioneering commercial DNA synthesis in the region, giving a platform to support research in synthetic and molecular biology.

Why does it matter?

Local manufacturing means little if products cannot reach customers. For a young life sciences company, distribution is often the hardest hurdle. Baynouna can now serve more customers, including industry and research teams, without carrying that burden alone.

For healthcare providers, the benefit is closer access to diagnostics made in their own region. Dr. Al Katheeri put it plainly: strong local capabilities across the life sciences value chain are essential to a resilient healthcare ecosystem. The pandemic showed how exposed import-dependent supply chains can be. Testing is the first thing everyone needs when a crisis hits.

The context

The agreement fits the UAE's stated ambition to become a regional hub for life sciences innovation and advanced manufacturing. It also reflects Mubadala Bio's wider strategy of building an integrated platform that spans manufacturing, distribution, logistics and commercialization.

The same logic is playing out across the GCC. Saudi Arabia's Vision 2030 pushes local pharmaceutical and medical manufacturing, and Gulf governments are investing in genomics and precision medicine. Those efforts need a commercial route to market, not just laboratories and funding.

That is what makes this deal worth watching. It pairs a homegrown scientific capability with a distributor that already has reach. The test will be volume: how many kits move, to which customers, and whether other UAE innovators follow the same path.

source

💡Did you know?

You can take your DHArab experience to the next level with our Premium Membership.
👉 Click here to learn more